Medicine & Life Sciences
Prostate-Specific Antigen
100%
Prostatic Neoplasms
65%
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
62%
Positron-Emission Tomography
56%
Membranes
56%
Molecular Imaging
34%
Neoplasms
32%
N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethyl-pyrazolo(1,5-a)pyrimidin-3-yl)-acetamide
20%
Brain
18%
Ligands
16%
Single-Photon Emission-Computed Tomography
16%
Glutamate Carboxypeptidase II
15%
Theranostic Nanomedicine
15%
Radiopharmaceuticals
13%
Positron Emission Tomography Computed Tomography
13%
Heterografts
12%
Nanoparticles
12%
Therapeutics
12%
Neuroimaging
11%
Magnetic Resonance Imaging
10%
N-(N-((S)-1,3-Dicarboxypropyl)carbamoyl)-4-(18F)fluorobenzyl-L-cysteine
9%
Fluorodeoxyglucose F18
9%
Animals
8%
Urea
8%
Single Photon Emission Computed Tomography Computed Tomography
8%
Protons
8%
3-(1,4-diazabicyclo(3.2.2)nonan-4-yl)-6-fluorodibenzo(b,d)thiophene 5,5-dioxide
8%
Prostate
8%
Castration
8%
Kidney
7%
Data Systems
7%
Radioactivity
6%
Molecular Weight
6%
Brain Neoplasms
6%
Nicotinic Receptors
6%
Injections
6%
Proteins
6%
Biomarkers
6%
fialuridine
5%
Peptides
5%
Somatostatin Receptors
5%
Thymidine Kinase
5%
Glioma
5%
human FOLH1 protein
5%
Optical Imaging
5%
Neuroglia
5%
Radiotherapy
5%
Radioisotopes
5%
Central Nervous System Vasculitis
5%
Glutamic Acid
5%